Group One Trading
ABCL icon

Group One Trading’s AbCellera Biologics ABCL Stock Holding History

Group One Trading’s Portfolio ABCL Stock Details ABCL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.33M Sell
297,400
-87,800
-23% -$429K ﹤0.01% 2079
2026
Q1 		$1.34M Sell
385,200
-72,900
-16% -$262K ﹤0.01% 2446
2025
Q4 		$1.57M Buy
458,100
+82,100
+22% +$366K ﹤0.01% 2487
2025
Q3 		$1.89M Buy
376,000
+216,200
+135% +$953K ﹤0.01% 2376
2025
Q2 		$548K Buy
159,800
+52,200
+49% +$130K ﹤0.01% 3316
2025
Q1 		$240K Buy
107,600
+18,500
+21% +$53.1K ﹤0.01% 3835
2024
Q4 		$261K Buy
89,100
+38,200
+75% +$106K ﹤0.01% 3729
2024
Q3 		$132K Buy
50,900
+1,800
+4% +$4.99K ﹤0.01% 3958
2024
Q2 		$145K Buy
49,100
+3,000
+7% +$11.4K ﹤0.01% 3661
2024
Q1 		$209K Sell
46,100
-273,300
-86% -$1.39M ﹤0.01% 3526
2023
Q4 		$1.82M Buy
319,400
+39,700
+14% +$184K ﹤0.01% 1951
2023
Q3 		$1.29M Sell
279,700
-28,000
-9% -$170K ﹤0.01% 2022
2023
Q2 		$1.99M Sell
307,700
-46,000
-13% -$314K 0.01% 1716
2023
Q1 		$2.67M Sell
353,700
-135,700
-28% -$1.23M 0.01% 1299
2022
Q4 		$4.96M Sell
489,400
-157,600
-24% -$1.82M 0.01% 1153
2022
Q3 		$6.4M Buy
647,000
+381,000
+143% +$4.18M 0.01% 987
2022
Q2 		$2.83M Sell
266,000
-390,500
-59% -$3.31M ﹤0.01% 1734
2022
Q1 		$6.4M Sell
656,500
-381,900
-37% -$3.62M 0.01% 1343
2021
Q4 		$14.8M Buy
1,038,400
+241,700
+30% +$3.67M 0.01% 836
2021
Q3 		$16M Buy
796,700
+662,400
+493% +$11.7M 0.02% 748
2021
Q2 		$2.96M Buy
134,300
+126,400
+1,600% +$3.49M ﹤0.01% 2230
2021
Q1 		$268K Buy
+7,900
New +$315K ﹤0.01% 4704

Other funds holding ABCL

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
TWC
TD Waterhouse Canada Toronto, Ontario, Canada $38B AUM 39.14% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Tudor Investment Corp
Tudor Investment Corp Stamford, Connecticut $71.9B AUM 42.37% 1-Year Est. Return

Group One Trading's ABCL Position: Q2 2026 in Review

Group One Trading reduced its AbCellera Biologics (ABCL) stake by 17% in Q2 2026, selling an estimated $197K and leaving 198,793 shares worth $1.56M. The position accounts for ﹤0.01% of the portfolio, ranked #2461.

Group One Trading first reported a position in ABCL in Q2 2021 and has held it in 19 quarters since. 150 funds tracked by Wall St. Rank hold ABCL as of Q2 2026.

  • Group One Trading held 198,793 shares of AbCellera Biologics worth $1.56M as of Q2 2026.
  • Group One Trading sold 40,340 AbCellera Biologics shares in Q2 2026, an estimated $197K.
  • AbCellera Biologics made up ﹤0.01% of Group One Trading's portfolio in Q2 2026, its #2461 holding.
  • Group One Trading first reported a position in AbCellera Biologics in Q2 2021 and has held it in 19 quarters since.
  • 150 funds tracked by Wall St. Rank held AbCellera Biologics as of Q2 2026.

Based on Group One Trading's 13F filing for Q2 2026, filed 14 Aug 2026.